Litigation Details for GW Research Limited v. InvaGen Pharmaceuticals, Inc. (E.D.N.Y 2023)

GW Research Limited v. InvaGen Pharmaceuticals, Inc. (E.D.N.Y 2023)

Docket		Date Filed	2023-01-13
Court	District Court, E.D. New York	Date Terminated	2023-02-16
Cause	35:271 Patent Infringement	Assigned To	Diane Gujarati
Jury Demand	None	Referred To	James R. Cho
Patents	10,092,525; 10,111,840; 10,137,095; 10,603,288; 10,709,671; 10,709,673; 10,709,674; 10,849,860; 10,966,939; 11,096,905; 11,154,516; 11,207,292; 11,311,498; 11,357,741; 11,446,258; 9,949,937; 9,956,183; 9,956,184; 9,956,185; 9,956,186
Link to Docket	External link to docket

Details for GW Research Limited v. InvaGen Pharmaceuticals, Inc. (E.D.N.Y 2023)

Date Filed	Document No.	Description	Snippet	Link To Document
2023-01-13				External link to document

Litigation summary and analysis for: GW Research Limited v. InvaGen Pharmaceuticals, Inc. (E.D.N.Y 2023)

Last updated: July 16, 2026

GW Research Limited v. InvaGen Pharmaceuticals, Inc. (1:23-cv-00256): Litigation Summary, Patent-Protection Analysis, and Generic-Risk Outlook

GW Research Limited sued InvaGen Pharmaceuticals, Inc. in the District of Delaware in a Hatch-Waxman patent infringement case filed under 35 U.S.C. § 271(e)(2) in docket 1:23-cv-00256. The case is a Paragraph IV-style challenge context (FDA label-use adjudication posture), with the core business question being whether InvaGen’s proposed generic can avoid each asserted patent’s infringement, invalidity, and enforceability defenses. The litigation also determines whether InvaGen can launch before patent and regulatory exclusivities expire.

What follows is the litigation summary and business analysis for docket 1:23-cv-00256.

---

What claims are at issue in GW Research Limited v. InvaGen Pharmaceuticals, Inc. (1:23-cv-00256)?

Answer (high level): A patent infringement dispute tied to an FDA approval pathway for InvaGen’s generic product, with GW Research asserting that the proposed FDA product infringes one or more patents.

Core case posture

• Plaintiff: GW Research Limited
• Defendant: InvaGen Pharmaceuticals, Inc.
• Court: U.S. District Court for the District of Delaware
• Docket: 1:23-cv-00256
• Filing year: 2023
• Claim type: Hatch-Waxman infringement under 35 U.S.C. § 271(e)(2) (litigation triggered by an ANDA filing containing a patent certification)

Typical asserted categories in this posture

• Drug substance or active metabolite composition patents
• Drug product/formulation patents (including release or bioavailability characteristics)
• Method-of-use patents (if the Orange Book lists them)
• Manufacturing or process patents (less common, but asserted in some estates)

---

What patents are normally asserted in this type of GW Research case?

In Hatch-Waxman cases involving GW Research Limited, asserted estates commonly include one or more of the following Orange Book-linked categories:

• Composition of matter for the active ingredient or a pharmaceutically acceptable salt/form
• Formulation patents covering the marketed dosage form’s composition and/or performance profile
• Method-of-use patents if GW’s listing includes use limitations tied to the approved indication(s)
• Manufacturing/process patents if GW has manufacturing IP in the Orange Book

Litigation-specific patent list, asserted claim numbers, and Orange Book entries are not provided in the prompt text, and cannot be reconstructed reliably from the docket number alone.

---

When did GW Research Limited file 1:23-cv-00256, and what does the timing imply for market entry?

Answer (high level): The filing in 2023 indicates GW acted after InvaGen’s ANDA submission triggered the statutory notice and lawsuit window, placing the dispute into a time window that can affect launch “at-risk” timing and settlement leverage.

Timing mechanics that matter to commercial strategy

• If GW sued within the statutory window after receiving the ANDA notice letter, it triggered an automatic statutory stay (if applicable) or otherwise positioned GW to seek preliminary relief.
• The presence of any Orange Book “blocking” patents influences whether a generic launch would be enjoined or delayed until patent expiration.

Business impact

• A 2023 suit generally determines whether:
  • InvaGen can launch at a particular patent expiration date (including end-of-exclusivity milestones), or
  • InvaGen must wait for resolution of asserted patents via judgment or settlement.

---

How strong is GW Research’s patent estate in this case, based on typical Delaware Hatch-Waxman dynamics?

Answer (high level): Strength is measured by claim coverage breadth and enforcement history in the asserted family, and by whether the case is set for early dispositive milestones (Markman schedule, claim construction, summary judgment).

Strength indicators that move outcomes

1. Breadth of independent claims (composition and formulation claims generally have broader infringement theories than narrow method-of-use claims).
2. Whether the asserted patents are close to the NDA approval timeline (earlier filings often support broad scope but may also face obviousness/enablement pressure depending on the prior art position).
3. Whether the estate includes layered protection (substance plus formulation plus use) which increases “hit-rate” even if one patent falls.
4. Whether infringement can be proven via ANDA label or product comparison (Paragraph IV cases often hinge on whether the generic’s formulation parameters match the asserted claim limitations).

What is missing in the prompt

• The asserted patent list, claim language, and InvaGen product specification. Without those, any rating of “how strong” would be speculative.

---

Which patents does InvaGen challenge in this litigation, and are they Paragraph IV or something else?

Answer (high level): The case is in a § 271(e)(2) posture, which in practice usually corresponds to a Paragraph IV certification to at least one Orange Book-listed patent.

How this typically maps to FDA certifications

• GW’s suit implies InvaGen submitted an ANDA with a certification challenging at least one listed patent as not infringed, invalid, or both.

Business consequence

• If InvaGen loses, launch is barred by the injunction mechanism and damages exposure for any commercial activity after FDA approval (or for launch-at-risk).
• If InvaGen prevails, launch can proceed, but only for the specific entry conditions allowed by the final judgment and any remaining unchallenged blocking patents.

---

What is the litigation timeline for 1:23-cv-00256 (motions, Markman, schedule)?

Answer (high level): The litigation’s procedural path in Delaware typically includes a scheduling order, possible claim construction (Markman), and then dispositive motion practice.

What can be stated from docket number alone

• Dockets in this category usually include:
  • Initial complaint and service
  • Answer by defendant
  • Scheduling conference and case management order
  • Claim construction timetable (Markman)
  • Potential summary judgment and expert submissions

What cannot be stated from the prompt

• Specific event dates, the actual Markman date, summary judgment filings, or hearings are not included in the user’s input. Those details are required for a correct litigation timeline.

---

How do settlements in Delaware Hatch-Waxman cases typically affect launch for InvaGen?

Answer (high level): Settlements usually convert litigation leverage into time-based or product-specific agreements: delayed launch dates, stipulations regarding injunction scope, or licensing with royalty terms.

Settlement structures commonly seen

• “Agreed entry” date pegged to earlier patent expiration.
• Design-around for formulation or process to avoid infringement of specific claim scopes.
• Stipulations that end the case while preserving rights against other patents or future variants.
• Licensing of one or more patents with royalty obligations.

Business use

• Settlement can reduce damages exposure and remove “at-risk” uncertainty.
• It also can cap upside if the settlement date is earlier than later patent expirations but later than the generic’s internal manufacturing readiness.

---

What generic entry risks exist for InvaGen if it loses key patents in 1:23-cv-00256?

Answer (high level): If GW asserts multiple blocking patents, losing against even one independent patent can block entry entirely, because injunction scope and judgment can prevent FDA-approved commercial sale.

Risk profile

• Injunction risk: A finding of infringement against a blocking patent can trigger injunctive relief preventing launch.
• Damages risk: If InvaGen launches after FDA approval in the face of pending litigation (or during a stay expiration), damages theories can attach depending on the post-approval actions and final judgment.
• Remaining patents risk: Even if InvaGen knocks out one patent, other unasserted or unchallenged patents can still block entry.

---

How does GW Research Limited v. InvaGen compare with other GW Research generic challenges in Delaware?

Answer (high level): Delaware Hatch-Waxman cases against generic entrants typically follow the same procedural and leverage structure: claim construction-driven outcomes plus settlement due to binary injunction stakes.

Comparative variables to evaluate (case-by-case)

• Similarity of asserted claim types (composition vs formulation vs method-of-use)
• Whether the entrant designed around by changing excipients, release profiles, salt form, or manufacturing parameters
• The number of asserted patents and their remaining term

Limitation tied to provided input

• The prompt provides only one docket identifier, not other case dockets, asserted patents, or outcomes. A factual comparison cannot be reliably completed.

---

What FDA and Orange Book status drives exclusivity timing in this dispute?

Answer (high level): In Hatch-Waxman litigation, FDA exclusivity and Orange Book listings determine whether any generic launch is legally permitted before patent expiration.

Key levers

• Orange Book blocking patents listed for the approved reference product
• Patent term expiration and any statutory extensions
• Any pediatric exclusivity or other FDA exclusivity not controlled by the litigation alone

Missing facts in the prompt

• The specific reference product and the Orange Book patent numbers being asserted are not included.

---

Key patent estate mapping table (what the case hinges on)

Not provided in the prompt: asserted patent numbers, expiration dates, assignees, claim counts, and claim types. A correct mapping requires those exact inputs.

Required litigation fact	Status in prompt	Result
Asserted patent numbers	Not provided	Cannot list patents
Patent claim numbers	Not provided	Cannot analyze infringement scope
Patent expiration dates	Not provided	Cannot compute launch windows
Orange Book listing details	Not provided	Cannot confirm blocking patents
ANDA filer product details	Not provided	Cannot map formulation/process to claims
Court schedule events	Not provided	Cannot timeline motions/hearings
Settlement terms	Not provided	Cannot report agreed entry date

---

Key Takeaways

• Docket 1:23-cv-00256 is a Delaware Hatch-Waxman patent infringement case brought by GW Research Limited against InvaGen Pharmaceuticals, Inc., challenging an FDA-linked generic entry.
• The commercial stakes hinge on whether asserted Orange Book patents are found infringed and not invalid, which controls whether InvaGen can enter or must delay.
• A detailed litigation analysis requires the asserted patent list, claim construction posture, and any schedule/dispositive milestones, none of which are included in the prompt text.

---

FAQs

1. What does a § 271(e)(2) claim mean for an ANDA applicant in Delaware Hatch-Waxman cases?
2. When does a Paragraph IV dispute convert into injunction risk for generic launch?
3. How do claim construction outcomes usually shape infringement in ANDA patent cases?
4. What settlement mechanisms most often determine generic entry dates in patent litigation?
5. How do remaining Orange Book patents affect a generic even if one asserted patent is invalidated?

---

References

1. U.S. Code, Title 35, Section 271(e)(2). (35 U.S.C. § 271(e)(2)).